EP Wealth Advisors LLC Takes Position in TransMedics Group, Inc. $TMDX

EP Wealth Advisors LLC purchased a new stake in shares of TransMedics Group, Inc. (NASDAQ:TMDX) during the 2nd quarter, HoldingsChannel reports. The fund purchased 15,401 shares of the company’s stock, valued at approximately $1,023,000.

A number of other hedge funds and other institutional investors have also made changes to their positions in TMDX. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its position in shares of TransMedics Group by 11.9% during the third quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 1,069,492 shares of the company’s stock worth $119,997,000 after purchasing an additional 113,817 shares during the period. Goldman Sachs Group Inc. grew its holdings in shares of TransMedics Group by 50.1% during the 4th quarter. Goldman Sachs Group Inc. now owns 965,931 shares of the company’s stock valued at $117,506,000 after acquiring an additional 322,353 shares in the last quarter. Geode Capital Management LLC increased its position in TransMedics Group by 0.4% in the 4th quarter. Geode Capital Management LLC now owns 816,474 shares of the company’s stock worth $99,339,000 after purchasing an additional 2,903 shares during the last quarter. Two Sigma Investments LP increased its holdings in TransMedics Group by 54.2% in the third quarter. Two Sigma Investments LP now owns 635,394 shares of the company’s stock worth $71,291,000 after buying an additional 223,409 shares during the last quarter. Finally, Price T Rowe Associates Inc. MD raised its holdings in shares of TransMedics Group by 43.2% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 569,970 shares of the company’s stock valued at $69,338,000 after purchasing an additional 171,810 shares in the last quarter. 99.67% of the stock is currently owned by institutional investors.

Insider Activity

In other news, Director Thomas J. Gunderson sold 9,624 shares of the stock in a transaction dated Monday, June 15th. The shares were sold at an average price of $75.06, for a total value of $722,377.44. Following the completion of the sale, the director owned 16,642 shares in the company, valued at $1,249,148.52. This represents a 36.64% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 6.90% of the stock is currently owned by insiders.

TransMedics Group Price Performance

Shares of NASDAQ:TMDX opened at $94.77 on Monday. The stock has a market cap of $3.28 billion, a price-to-earnings ratio of 24.36 and a beta of 1.90. The company has a quick ratio of 6.07, a current ratio of 6.62 and a debt-to-equity ratio of 1.62. TransMedics Group, Inc. has a 12-month low of $60.10 and a 12-month high of $156.00. The business’s 50 day moving average is $77.49 and its 200 day moving average is $95.05.

TransMedics Group (NASDAQ:TMDX) last released its quarterly earnings results on Tuesday, August 4th. The company reported $0.44 EPS for the quarter, missing analysts’ consensus estimates of $0.50 by ($0.06). TransMedics Group had a net margin of 22.69% and a return on equity of 15.88%. The company had revenue of $189.95 million during the quarter, compared to analysts’ expectations of $184.00 million. During the same period in the previous year, the company posted $0.92 earnings per share. The company’s quarterly revenue was up 20.7% compared to the same quarter last year. On average, sell-side analysts forecast that TransMedics Group, Inc. will post 1.47 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several equities analysts recently issued reports on the company. TD Cowen restated a “buy” rating and set a $120.00 price target on shares of TransMedics Group in a research note on Wednesday, July 1st. Oppenheimer downgraded TransMedics Group from an “outperform” rating to a “market perform” rating in a research note on Wednesday, May 6th. Stifel Nicolaus boosted their price target on TransMedics Group from $75.00 to $80.00 and gave the company a “hold” rating in a research note on Thursday, June 18th. Zacks Research cut TransMedics Group from a “hold” rating to a “strong sell” rating in a report on Monday, July 6th. Finally, Weiss Ratings cut TransMedics Group from a “hold (c)” rating to a “hold (c-)” rating in a report on Tuesday, July 28th. Six research analysts have rated the stock with a Buy rating, six have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company has an average rating of “Hold” and an average price target of $124.18.

TransMedics Group Profile

TransMedics Group, Inc is a medical device company headquartered in Andover, Massachusetts, that specializes in advanced organ preservation and transport systems for transplantation. The company’s flagship technology, the Organ Care System (OCS), maintains donor organs in a near-physiologic, warm, beating state during transportation, with the aim of extending preservation times and improving post‐transplant outcomes. TransMedics’ solutions address a critical need in transplantation by reducing ischemic injury and expanding the donor organ pool.

TransMedics currently markets two commercially available OCS platforms.